Rein Therapeutics, Inc. (RNTX) stock
Close on Nov 13, 2026Market cap $47.63MP/E –Yield 0.00%
Rein Therapeutics, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $47.63M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $47.63M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.86
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$49.72M
- EPS, diluted
- -$1.44
- Book value per share
- $0.60
- Diluted shares
- 88M
Trading
- Previous close
- $0.56
- Open
- $0.55
- Day's range
- $0.50 – $0.57
- Volume
- 488,672
- Average volume (20 days)
- 349,337
- Beta (5 years)
- 1.42
- 52-week range
- $0.50 – $2.10
- RSI (14 days)
- 37.3
- Volatility (1 year)
- 85.3%
- Relative volume
- 1.16×
- WACC
- 12.2%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNTX | S&P 500 | Difference | RNTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.8% | -3.0% | −23.8 pts | ||
| 3 months | -29.9% | -2.8% | −27.1 pts | ||
| Year to date | -52.4% | +11.5% | −63.9 pts | ||
| 1 year | -59.1% | +13.5% | −72.6 pts | ||
| 3 years | -67.3% | +77.7% | −145.0 pts | -31.1% | +21.1% |
| 5 years | -96.8% | +72.6% | −169.4 pts | -49.8% | +11.5% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rein Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- News
- Results
About Rein Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical business that develops novel therapeutics targeting orphan pulmonary and fibrosis indications with limited or no approved therapies. Its primary pipeline candidate is LTI-03, an inhaled peptide therapeutic derived from the Cav1 protein designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis. The company also developed LTI-01, a proenzyme for treating loculated pleural effusion, alongside preclinical programs for cystic fibrosis and systemic fibrosis, although active development on these secondary programs is paused. Because its drug candidates remain in clinical and preclinical development, the company has no commercialized products, generates no product sales revenue, and currently lacks commercial customers or internal sales, marketing, and distribution infrastructure.
Company profile, executives and historyRein Therapeutics stock: common questions
What is Rein Therapeutics's stock price?
RNTX closed at $0.55 on Nov 13, 2026, down 1.41% on the day. Over the past 52 weeks it traded between $0.50 and $2.10.
What is Rein Therapeutics's market cap?
Rein Therapeutics was worth $47.63M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is RNTX's P/E ratio?
Rein Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.44), so it has no meaningful P/E ratio.
How much revenue does Rein Therapeutics make?
Rein Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026.
Does Rein Therapeutics pay a dividend?
No. Rein Therapeutics has not paid a cash dividend over the last twelve months.
How has RNTX stock performed over the past year?
Including dividends, RNTX returned -59.1% over the past year, against +13.5% for the S&P 500.
How many RNTX shares are sold short?
1M shares were sold short at the latest FINRA report, 0.91% of the float, or 2.1 days of average trading volume.
Who are Rein Therapeutics's competitors?
Companies most similar to Rein Therapeutics by business, industry and size include GRI, TVRD, CMMB, GHRS, MLYS.
See a number that looks wrong?